Patrick S. Gagnon
 
                    Education
Master’s, economics, University of Quebec in Montreal; baccalaureate, economics, Laval University
Summary of Experience
Mr. Gagnon is an economist who specializes in applying advanced econometric methods to health economics and outcomes research (HEOR), with a particular focus in database analyses. He has participated in the development and implementation of data analytics throughout the product life cycle, from pre-marketing to post-marketing real-world evidence (RWE) generation. His areas of expertise include economic burden assessment, health economic modeling, predictive analytics, and stakeholder submissions. Mr. Gagnon has conducted analyses for pharmaceutical companies in a variety of therapeutic areas, including cirrhosis, irritable bowel syndrome, opioid-induced constipation, macular edema, scleroderma, sickle cell disease, Alzheimer’s disease, post-traumatic stress disorder, attention deficit hyperactivity disorder, major depressive disorder, bipolar disorder, and oncology. His work has been used to inform reimbursement decisions in the US and has been presented at numerous conferences and published in multiple peer-reviewed journals, such as The Journal of Clinical Psychiatry, the Journal of Managed Care & Specialty Pharmacy, BMC Psychiatry, BMJ Open Ophthalmology, and PLOS One.
- 
                                                        Impact of living with an adult with depressive symptoms among households in the United StatesJournal of Affective Disorders, 2024 
 2024Greenberg P, O'Callaghan L, Fournier AA, Gagnon-Sanschagrin P, Maitland J, Chitnis A 
- 
                                                        Patient journey of civilian adults diagnosed with posttraumatic stress disorder—A chart review studyCurrent Medical Research and Opinion, 2024 
 2024Davis LL, Urganus A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Bellefleur R, Cloutier M, Guérin A, Aggarwal J 
- 
                                                        Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with DiarrheaAdvances in Therapy, 2024 
 2024Lacy B, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre A 
- 
                                                        The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database studyJournal of Medical Economics, 2024 
 2024Gagnon-Sanschagrin P, Sanon M, Davidson M, Willey C, Kachroo S, Hoops T, Naessens D, Guerin A, Cloutier M 
- 
                                                        Treatment Patterns among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims AnalysisAdvances in Therapy, 2023 
 2023Schein J, Childress A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Cloutier M, Guérin A 
- 
                                                        The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)Advances in Therapy, 2023 
 2023Greenberg P, Chitnis A, Louie D, Suthoff E, Chen SY, Maitland J, Gagnon-Sanschagrin P, Fournier AA, Kessler RC 
- 
                                                        Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims studyCurrent Medical Research and Opinion, 2023 
 2023Davis LL, Urganus A, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A, Aggarwal J 
- 
                                                        Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costsJournal of Medical Economics, 2023 
 2023Jesudian AB, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Chen J, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA 
- 
                                                        Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning ApproachBMC Psychiatry, 2022 
 2022Gagnon-Sanschagrin P, Schein J, Urganis A, Serra E, Liang Y, Musingarimi P, Cloutier M, Guérin A, Davis L 
- 
                                                        Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysisBMC Psychiatry, 2022 
 2022Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A 
- 
                                                        Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspectiveJournal of Medical Economics, 2022 
 2022Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P 
- 
                                                        The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal PerspectiveThe Journal of Clinical Psychiatry, 2022 
 2022Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR 
- 
                                                        Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspectiveJournal of Managed Care & Specialty Pharmacy, 2022 
 2022Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P 
- 
                                                        Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency DepartmentAdvances in Therapy, 2022 
 2022Peacock WF, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guérin A, Joseph G 
- 
                                                        Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims studyCurrent Medical Research and Opinion, 2021 
 2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P 
- 
                                                        Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stageJournal of Medical Economics, 2021 
 2021Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Guérin A, Cloutier M 
- 
                                                        Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspectiveBMJ Open Opthalmology, 2021 
 2021Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bédard J, Guérin A, Albini TA 
- 
                                                        Impact of agitation in long-term care residents with dementia in the United StatesInternational Journal of Geriatric Psychiatry, 2021 
 2021Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G 
- 
                                                        Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payersJournal of Medical Economics, 2020 
 2020Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Guerin A 
- 
                                                        The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey AnalysisJournal of Managed Care & Specialty Pharmacy, 2019 
 2019Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ 
- 
                                                        Institutionalization risk and costs associated with agitation in Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2019 
 2019Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS 
- 
                                                        Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast CancerAdvances in Therapy. 2018 Sep;35(9):1356-1367 
 2018Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, Small T 
- 
                                                        Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal WomenAdvances in Therapy. Mar 20 2018 
 2018Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA 
- 
                                                        Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast CancerAdvances in Therapy. April 13, 2018 
 2018Dalal AA, Gagnon-Sanschagrin P, Burne R, Guérin A, Gauthier G, Small T, Niravath P 
- 
                                                        Assessment of costs associated with adverse events in patients with cancerPloS One. 2018;13(4):e0196007 
 2018Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A 
- 
                                                        Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United StatesAdvances in Therapy, 2018 Oct;35(10):1671-1685 
 2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ 
- 
                                                        Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based AnalysisJ Drugs Dermatol. Feb 1 2018;17(2):180-186 
 2018Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A 
- 
                                                        Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast CancerAdvances in Therapy. 2018 Aug;35(8):1251-1264 
 2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA 
- 
                                                        A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United StatesJournal of Medical Economics. 2018 Dec;21(12):1183-1190 
 2018Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guérin A 
- 
                                                        Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populationsJournal of Medical Economics. 2018 Jun;21(6):556-563 
 2018Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ 
- 
                                                        Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based AnalysisJournal of Drugs in Dermatology, 2018 
 2018Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A 
- 
                                                        Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequencyJournal of Managed Care and Specialty Pharmacy. 2017;23(2):214-224 
 2017Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ 
- 
                                                        Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United StatesJournal of Medical Economics. Jan 2017;20(1):63-71 
 2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. 
- 
                                                        Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia(1)Journal of Medical Economics. Jan 2017;20(1):63-71 
 2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L 
- 
                                                        May 8, 2023
- 
                                                        May 31, 2024
- 
                                                    June 4, 2024
- 
                                                    February 26, 2024
- 
                                                    October 23, 2023
- 
                                                    June 27, 2023
- 
                                                    March 22, 2023
- 
                                                    October 17, 2022
- 
                                                    April 13, 2021
 
        